GOREISAN for Heart Failure (GOREISAN-HF) Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1179 participants.
Also called NCT04691700
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,179 participants
- Sponsor
- Registry
-
NCT04691700
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04691700. Randomized; no masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GOREISAN for Heart Failure (GOREISAN-HF) Trial
- Acronym
- GOREISAN-HF
- Condition
- Heart Failure
- Condition
- Edema
- Condition
- Traditional Japanese Medicine
- Condition
- Kampo Medicine
- Condition
- Clinical Trial
- Intervention (Drug)
- Goreisan
- Intervention (Drug)
- Standard Treatment
- Lead sponsor
- Takeshi Morimoto
Record details
- Record id
cardio:ct-nct04691700- Content hash
fb6a07a419a83265276e77d564898c2d952f01a38f26a0f3a5e5713c0f731d5c